Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Eisai begins enrolment for phase III trial of new Alzheimer’s therapy

Eisai begins enrolment for phase III trial of new Alzheimer’s therapy

7th November 2016

Eisai has commenced patient enrolment for a new clinical trial of E2609, an innovative therapy for early Alzheimer's disease.

The MISSION AD1 trial is the first study in the wider phase III clinical programme MISSION AD, which will evaluate the beta secretase-cleaving enzyme inhibitor E2609 in patients with early Alzheimer's disease in the United States. 

Developed in collaboration with Biogen, the drug is designed to decrease the formation of toxic amyloid beta peptide aggregates and amyloid plaques in the brain, thereby slowing disease progression.

MISSION AD1 will assess the efficacy and safety of E2609 in 1,330 patients with early Alzheimer's disease over a treatment period of 24 months. Eisai and Biogen are currently in consultation with regulatory authorities in the EU and Japan over the further development of the drug.

Dr Lynn Kramer, chief clinical officer and chief medical officer of Eisai's neurology business, said: "Through the initiation of MISSION AD1 and similar clinical trials, we hope to demonstrate the value of this compound for those who suffer from early Alzheimer's disease."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801827956-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.